[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@mtheory11bio Chris Carper
Chris Carper posts on X about $alec, $tecx, $azn, $bhvn the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +20%
- X Months XXXXXXX +13%
- X Year XXXXXXX -XX%
Mentions: X #
- X Week X no change
- X Month XX no change
- X Months XX +33%
- X Year XXX -XX%
Followers: XXXXX #
- X Week XXXXX +0.23%
- X Month XXXXX +4.80%
- X Months XXXXX +11%
- X Year XXXXX +13%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks currencies
Social topic influence $alec #1, $tecx, $azn, $bhvn, jk, number of, $crvs, $kymr, $500m, $35b
Top assets mentioned AstraZeneca PLC (AZN) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Kymera Therapeutics, Inc. Common Stock (KYMR)
Top Social Posts #
Top posts by engagements in the last XX hours
"Like the setup for $TECX as expectations are low heading into the HFrEF + $AZN Re-PHIRE readouts. The primary endpoint for Re-PHIRE is change in PVR vs pbo but w/ the inclusion of ipcPH patients (which have normal PVR) secondary endpoints and subgroups should be more important"
X Link @mtheory11bio 2025-10-15T14:53Z 5245 followers, 2595 engagements
"$BHVN is interesting because would the FDA say haha j/k in a CRL if troriluzole hit X pre-specified primary and secondary endpoints in the RWE study that the FDA helped design"
X Link @mtheory11bio 2025-10-02T13:36Z 5243 followers, 9458 engagements
"1/ $ALEC reduced the number of patients for INFRONT-3 to 90-100 symptomatic patients vs the previous XXX total patients based on a blinded SSRE. They stated that the SSRE demonstrated the variability of disease progression is considerably less than their initial estimates"
X Link @mtheory11bio 2025-10-07T16:43Z 5243 followers, 2239 engagements
"$CRVS $KYMR Theres room for multiple winners in the oral AD space but this valuation gap is interesting"
X Link @mtheory11bio 2025-09-17T17:02Z 5243 followers, 4892 engagements
"@Jonny_fun_guy Just in terms of INFRONT-3 success I think $ALEC would get some credit for success by elevating PGRN in other indications thus validating the $XXX upfront they received from GSK. Im not as concerned about commercial prospects for this one indication while its trading at $3"
X Link @mtheory11bio 2025-10-07T18:05Z 5241 followers, XXX engagements